NRF1 and Miyoshi myopathy: TCF11/Nrf1-mediated proteasome re-synthesis (see the scheme in Figure 1A) is an attractive target for therapeutic intervention, especially for MM and mantle cell lymphoma, which are currently treated with proteasome inhibitors [5,11].